Descriptor English: | Apolipoprotein C-III | ||||
Descriptor Spanish: |
Apolipoproteína C-III
| ||||
Descriptor Portuguese: | Apolipoproteína C-III | ||||
Descriptor French: | Apolipoprotéine C-III | ||||
Entry term(s): |
Apo C III Apo C III 2 Apo C-III Apo C-III, Sialyl Apo C-III-2 ApoC III ApoC-III Apolipoprotein C III Apolipoprotein C III 0 Apolipoprotein C III 1 Apolipoprotein C-III, Sialyl Apolipoprotein C-III-0 Apolipoprotein C-III-1 Apolipoprotein CIII Sialyl Apo C III Sialyl Apo C-III Sialyl Apolipoprotein C III Sialyl Apolipoprotein C-III |
||||
Tree number(s): |
D10.532.091.400.875 D12.776.070.400.400.875 D12.776.521.120.400.875 |
||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D053305 | ||||
Scope note: | A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2). |
||||
Allowable Qualifiers: |
AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis DE drug effects DF deficiency EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PH physiology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UL ultrastructure UR urine |
||||
Previous Indexing: |
Apolipoproteins C (1977-2006) |
||||
Public MeSH Note: | 2007; APOLIPOPROTEIN C-III was indexed under APOLIPOPROTEINS C 1985-2006 & under APOLIPOPROTEINS 1979-1984 |
||||
History Note: | 2007; use APOLIPOPROTEIN C-III (NM) 1979-2006 |
||||
DeCS ID: | 52264 | ||||
Unique ID: | D053305 | ||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||
Date Established: | 2007/01/01 | ||||
Date of Entry: | 2006/07/05 | ||||
Revision Date: | 2013/07/09 |
-
-
CHEMICALS AND DRUGS
Lipids [D10]Lipids -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins
|
Apolipoprotein C-III
- Preferred
Apolipoprotein C-III-1
- Narrower
ApoC-III
- Narrower
Apolipoprotein C-III-0
- Narrower
Sialyl Apo C-III
- Narrower
Apo C-III-2
- Narrower
Concept UI |
M0073736 |
Scope note | A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2). |
Preferred term | Apolipoprotein C-III |
Entry term(s) |
Apo C III Apo C-III Apolipoprotein C III Apolipoprotein CIII |
Concept UI |
M0073732 |
Preferred term | Apolipoprotein C-III-1 |
Entry term(s) |
Apolipoprotein C III 1 |
Concept UI |
M0489164 |
Preferred term | ApoC-III |
Entry term(s) |
ApoC III |
Concept UI |
M0073731 |
Preferred term | Apolipoprotein C-III-0 |
Entry term(s) |
Apolipoprotein C III 0 |
Concept UI |
M0073734 |
Preferred term | Sialyl Apo C-III |
Entry term(s) |
Apo C-III, Sialyl Apolipoprotein C-III, Sialyl Sialyl Apo C III Sialyl Apolipoprotein C III Sialyl Apolipoprotein C-III |
Concept UI |
M0073729 |
Preferred term | Apo C-III-2 |
Entry term(s) |
Apo C III 2 |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey